Cargando…

Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans

Changes of glycosylation pattern in serum proteins have been linked to various diseases including cancer, suggesting possible development of novel biomarkers based on the glycomic analysis. In this study, N-linked glycans from human serum were quantitatively profiled by matrix-assisted laser desorpt...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jae-Han, Park, Chang Won, Um, Dalho, Baek, Ki Hwang, Jo, Yohahn, An, Hyunjoo, Kim, Yangsun, Kim, Tae Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932261/
https://www.ncbi.nlm.nih.gov/pubmed/24648610
http://dx.doi.org/10.1155/2014/634289
_version_ 1782304773641338880
author Kim, Jae-Han
Park, Chang Won
Um, Dalho
Baek, Ki Hwang
Jo, Yohahn
An, Hyunjoo
Kim, Yangsun
Kim, Tae Jin
author_facet Kim, Jae-Han
Park, Chang Won
Um, Dalho
Baek, Ki Hwang
Jo, Yohahn
An, Hyunjoo
Kim, Yangsun
Kim, Tae Jin
author_sort Kim, Jae-Han
collection PubMed
description Changes of glycosylation pattern in serum proteins have been linked to various diseases including cancer, suggesting possible development of novel biomarkers based on the glycomic analysis. In this study, N-linked glycans from human serum were quantitatively profiled by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and compared between healthy controls and ovarian cancer patients. A training set consisting of 40 healthy controls and 40 ovarian cancer cases demonstrated an inverse correlation between P value of ANOVA and area under the curve (AUC) of each candidate biomarker peak from MALDI-TOF MS, providing standards for the classification. A multibiomarker panel composed of 15 MALDI-TOF MS peaks resulted in AUC of 0.89, 80~90% sensitivity, and 70~83% specificity in the training set. The performance of the biomarker panel was validated in a separate blind test set composed of 23 healthy controls and 37 ovarian cancer patients, leading to 81~84% sensitivity and 83% specificity with cut-off values determined by the training set. Sensitivity of CA-125, the most widely used ovarian cancer marker, was 74% in the training set and 78% in the test set, respectively. These results indicate that MALDI-TOF MS-mediated serum N-glycan analysis could provide critical information for the screening of ovarian cancer.
format Online
Article
Text
id pubmed-3932261
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39322612014-03-19 Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans Kim, Jae-Han Park, Chang Won Um, Dalho Baek, Ki Hwang Jo, Yohahn An, Hyunjoo Kim, Yangsun Kim, Tae Jin Dis Markers Research Article Changes of glycosylation pattern in serum proteins have been linked to various diseases including cancer, suggesting possible development of novel biomarkers based on the glycomic analysis. In this study, N-linked glycans from human serum were quantitatively profiled by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and compared between healthy controls and ovarian cancer patients. A training set consisting of 40 healthy controls and 40 ovarian cancer cases demonstrated an inverse correlation between P value of ANOVA and area under the curve (AUC) of each candidate biomarker peak from MALDI-TOF MS, providing standards for the classification. A multibiomarker panel composed of 15 MALDI-TOF MS peaks resulted in AUC of 0.89, 80~90% sensitivity, and 70~83% specificity in the training set. The performance of the biomarker panel was validated in a separate blind test set composed of 23 healthy controls and 37 ovarian cancer patients, leading to 81~84% sensitivity and 83% specificity with cut-off values determined by the training set. Sensitivity of CA-125, the most widely used ovarian cancer marker, was 74% in the training set and 78% in the test set, respectively. These results indicate that MALDI-TOF MS-mediated serum N-glycan analysis could provide critical information for the screening of ovarian cancer. Hindawi Publishing Corporation 2014 2014-02-04 /pmc/articles/PMC3932261/ /pubmed/24648610 http://dx.doi.org/10.1155/2014/634289 Text en Copyright © 2014 Jae-Han Kim et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kim, Jae-Han
Park, Chang Won
Um, Dalho
Baek, Ki Hwang
Jo, Yohahn
An, Hyunjoo
Kim, Yangsun
Kim, Tae Jin
Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans
title Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans
title_full Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans
title_fullStr Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans
title_full_unstemmed Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans
title_short Mass Spectrometric Screening of Ovarian Cancer with Serum Glycans
title_sort mass spectrometric screening of ovarian cancer with serum glycans
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932261/
https://www.ncbi.nlm.nih.gov/pubmed/24648610
http://dx.doi.org/10.1155/2014/634289
work_keys_str_mv AT kimjaehan massspectrometricscreeningofovariancancerwithserumglycans
AT parkchangwon massspectrometricscreeningofovariancancerwithserumglycans
AT umdalho massspectrometricscreeningofovariancancerwithserumglycans
AT baekkihwang massspectrometricscreeningofovariancancerwithserumglycans
AT joyohahn massspectrometricscreeningofovariancancerwithserumglycans
AT anhyunjoo massspectrometricscreeningofovariancancerwithserumglycans
AT kimyangsun massspectrometricscreeningofovariancancerwithserumglycans
AT kimtaejin massspectrometricscreeningofovariancancerwithserumglycans